ClinicalTrials.gg
CompletedNCT00215423Updated Nov 11, 2010

Study in Patients With COPD

A Phase 2 interventional study of Formoterol Fumarate in COPD and Chronic Obstructive Pulmonary Disease, sponsored by Dey. Completed at 7 sites in United States. Open to participants aged 5 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-11-11.

Sponsored by Dey (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
5 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
57th of 89
49 · median 120
Phase 2
12 of 89
none open now
Registered
4th of 89
by date
Lead sponsor
11 of 89
Dey

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 57th largest by enrollment, is one of 12 in phase 2, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 5 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug

03

Conditions studied

  • COPD
  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
  • Chronic Obstructive Pulmonary Disease
  • Formoterol Fumarate
  • Formoterol
04

Who can participate

Ages eligible
5 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of
  • History of cigarette smoking

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of asthma
  • Significant pulmonary disease other than
  • Other significant major organ disease(s)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
49 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Measure of lung function

Secondary outcomes

  1. Change in lung function, as well as vital signs

  2. Physical Exam results, adverse event reporting, etc

07

Study locations

7 sites
  • Research Site
    Phoenix, Arizona 85006-2666, United States
  • Research Site
    Wheat Ridge, Colorado 80033, United States
  • Research Site
    Hines, Illinois 60141, United States
  • Research Site
    Shawnee Mission, Kansas 66216, United States
  • Research Site
    Butte, Montana 59701, United States
  • Research Site
    Omaha, Nebraska 68134, United States
  • Research Site
    Medford, Oregon 97504, United States
08

References and documents

Publications

  • Gross NJ, Kerwin E, Levine B, Kim KT, Denis-Mize K, Hamzavi M, Carpenter M, Rinehart M. Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Pulm Pharmacol Ther. 2008 Oct;21(5):818-23. doi: 10.1016/j.pupt.2008.07.002. Epub 2008 Jul 8. PubMed 18655841 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 11, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00215423
Lead sponsor
Dey
First posted
Sep 22, 2005
Primary completion
Dec 2003
Completion
Sep 2005
Last update
Nov 11, 2010
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion